Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Inter-ovarian differences in ultrasound markers of ovarian size in women with polycystic ovary syndrome

  • Chun, Sungwook (Department of Obstetrics and Gynecology, Inje University Haeundae Paik Hospital, Inje University College of Medicine)
  • Received : 2019.06.27
  • Accepted : 2019.08.30
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The aim of this study was to establish whether differences in ovarian size exist between the right and the left ovary of the same individual in women with polycystic ovary syndrome. Methods: In total, 206 Korean women with polycystic ovary syndrome were included in this study. In all participants, a transvaginal or transrectal ultrasound examination was conducted in the early follicular phase of the menstrual cycle. Results: A significant linear correlation was found between the two ovaries with regard to antral follicle count and ovarian volume. The mean antral follicle count in the right ovary (26.75 ± 11.72) was significantly higher than that in the left ovary (23.98 ± 10.85), and the mean volume of the right ovary (11.06 ± 5.17 cm3) was significantly different from that of the left ovary (9.12 ± 4.89 cm3). Conclusion: Ovarian size is different between the right and the left ovary in women with polycystic ovary syndrome.

Keywords

References

  1. Aubuchon M, Burney RO, Schust DJ, Yao MW. Infertility and Assisted Reproductive Technology. In: Berek JS, Novak E, editors. Berek & Novak's gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 1133-89.
  2. Practice Committee of the American Society for Reproductive Medicine. Aging and infertility in women. Fertil Steril 2006;86(5 Suppl 1):S248-52.
  3. Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
  4. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003;9:505-14. https://doi.org/10.1093/humupd/dmg044
  5. Deb S, Kannamannadiar J, Campbell BK, Clewes JS, Raine-Fenning NJ. The interovarian variation in three-dimensional ultrasound markers of ovarian reserve in women undergoing baseline investigation for subfertility. Fertil Steril 2011;95:667-72. https://doi.org/10.1016/j.fertnstert.2010.09.031
  6. Chun S, Cho HJ, Ji YI. Comparison of early postoperative decline of serum antiMullerian hormone levels after unilateral laparoscopic ovarian cystectomy between patients categorized according to histologic diagnosis. Taiwan J Obstet Gynecol 2016;55:641-645. https://doi.org/10.1016/j.tjog.2015.06.016
  7. Iwase A, Hirokawa W, Goto M, Takikawa S, Nagatomo Y, Nakahara T, et al. Serum anti-Mullerian hormone level is a useful marker for evaluating the impact of laparoscopic cystectomy on ovarian reserve. Fertil Steril 2010;94:2846-9. https://doi.org/10.1016/j.fertnstert.2010.06.010
  8. Kuzbari O, Doralis J, Peterson CM. Endocrine disorders. In: Berek JS, Novak E, editors. Berek & Novak's gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 1075-80.
  9. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  10. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598-603. https://doi.org/10.1093/humrep/deg115
  11. Buckett WM, Bouzayen R, Watkin KL, Tulandi T, Tan SL. Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 1999;14:618-21. https://doi.org/10.1093/humrep/14.3.618
  12. Chun S. Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Mullerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med 2014;41:86-91. https://doi.org/10.5653/cerm.2014.41.2.86
  13. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod 2011;26:214-20. https://doi.org/10.1093/humrep/deq303
  14. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-31. https://doi.org/10.1093/humrep/den239
  15. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7. https://doi.org/10.1093/humrep/deh098
  16. Ismail SR. An evaluation of the incidence of right-sided ovarian cystic teratoma visualized on sonograms. J Diagn Med Sonogr 2005;21:336-42. https://doi.org/10.1177/8756479305279035
  17. Pena JE, Ufberg D, Cooney N, Denis AL. Usefulness of Doppler sonography in the diagnosis of ovarian torsion. Fertil Steril 2000;73:1047-50. https://doi.org/10.1016/S0015-0282(00)00487-8
  18. Jokubkiene L, Sladkevicius P, Valentin L. Ovarian size and vascularization as assessed by three-dimensional grayscale and power Doppler ultrasound in asymptomatic women 20-39 years old using combined oral contraceptives. Contraception 2012;86:257-67. https://doi.org/10.1016/j.contraception.2011.12.013
  19. Merz E, Miric-Tesanic D, Bahlmann F, Weber G, Wellek S. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol 1996;7:38-42. https://doi.org/10.1046/j.1469-0705.1996.07010038.x
  20. Tugrul S, Oral O, Guclu M, Kutlu T, Uslu H, Pekin O. Significance of Doppler ultrasonography in the diagnosis of polycystic ovary syndrome. Clin Exp Obstet Gynecol 2006;33:154-8.
  21. Sokol ER, Genadry R, Anderson JR. Anatomy and embryology. In: Berek JS, Novak E, editors. Berek & Novak's gynecology. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p. 62-111.
  22. Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil Steril 2003;80:116-22. https://doi.org/10.1016/S0015-0282(03)00544-2
  23. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-18. https://doi.org/10.1093/humrep/dey256

Cited by

  1. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome vol.106, pp.9, 2021, https://doi.org/10.1210/clinem/dgab320